Venus Remedies unveils Taxedol in India

09 Jul 2012 Evaluate

Venus Remedies, a leading research based global pharmaceutical company has introduced for the first time a nanotechnology based ‘Ready-to-Use’ Single Vial Docetaxel in the domestic market under the brand name ‘Taxedol’. Taxedol is ready to use single vial formulation available in three strengths 20mg/0.5 ml, 80mg/2 ml and 120mg/3ml.

Taxedol (Docetaxel) is a single unit stable, pharmaceutical formulation which has lesser impurities in comparison to innovator product. This one vial formulation of Docetaxel will not only make the administration of the drug easier by introducing the premix solution but at the same time will provide enhanced safety to patients and para-medical staff. Furthermore, the nano-scale size of the formulation results in improved penetration, higher efficacy, improved safety and lesser side effects.

A semi-synthetic cytostatic taxane analogue, Docetaxel is considered as one of the most effective and successful oncology products, which is used mainly for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, head and neck cancer and ovarian cancer.

Taxedol, a ‘Ready-to-Use’ single vial will not only weed out the competition from other players in the market but the company is hopeful of capturing significant share in Rs 1,500 crore Indian Cancer Drug Industry, which is speculated to show a steady growth over the coming few years.

Venus Remedies Share Price

748.00 2.80 (0.38%)
08-Dec-2025 09:30 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1796.25
Dr. Reddys Lab 1274.40
Cipla 1512.50
Zydus Lifesciences 934.40
Lupin 2094.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×